…
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers CelluSTAT hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, nursing homes and assisted living, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. The company was incorporated in 1997 and is headquartered in Mount Laurel, New Jersey.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public information on United Health Products Inc (OTCQB: UEEC) is sparse, with filings and coverage offering limited detail on its core business and revenue model. Long-term growth drivers are not well documented; prospective upside depends on improved disclosure, execution of a clarified strategy and access to capital, which investors should monitor.
Key risks include limited transparency and public disclosure, thin liquidity and volatile OTCQB trading, possible lack of audited financials or operating history, and execution and financing risk.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -2.67M | -2.00M | -2.62M | -1.69M | -30.55M |
| Net income | -2.67M | -2.00M | -2.62M | -1.69M | -31.17M |
| Selling general administrative | 1.99M | 0.04M | 0.02M | 2.20M | 29.56M |
| Selling and marketing expenses | - | - | 1.80M | - | - |
| Gross profit | - | - | -0.00M | 0.02M | 0.00M |
| Reconciled depreciation | 0.00M | 0.00M | 0.00M | 0.00M | - |
| Ebit | - | - | -2.51M | -2.80M | -29.80M |
| Ebitda | - | - | -2.50M | -1.40M | -29.50M |
| Depreciation and amortization | - | - | 0.00M | 1.41M | 0.30M |
| Non operating income net other | - | - | - | 1.11M | -0.75M |
| Operating income | -2.26M | -2.01M | -2.43M | -2.80M | -29.80M |
| Other operating expenses | - | - | 2.43M | 2.84M | 29.80M |
| Interest expense | 0.20M | 0.11M | 0.12M | 0.08M | 0.62M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Net interest income | -0.20M | -0.11M | -0.12M | -0.08M | -0.62M |
| Income tax expense | - | - | 0.00M | -0.00M | 0.62M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.04M | 0.00M |
| Total operating expenses | 2.26M | 0.04M | 2.43M | 2.82M | 29.80M |
| Cost of revenue | - | - | 0.00M | 0.02M | 0.00M |
| Total other income expense net | -0.21M | 0.12M | -0.20M | 1.11M | -0.75M |
| Net income from continuing ops | -2.67M | -2.00M | -2.82M | -1.69M | -30.55M |
| Net income applicable to common shares | - | - | - | -1.69M | -30.55M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 0.32M | 0.27M | 0.28M | 0.35M | 0.03M |
| Intangible assets | 0.02M | 0.03M | 0.03M | 0.04M | - |
| Other current assets | 0.04M | 0.02M | 0.02M | 0.02M | 0.01M |
| Total liab | 4.19M | 2.71M | 2.00M | 2.42M | 1.17M |
| Total stockholder equity | -3.88M | -2.44M | -1.71M | -2.06M | -1.14M |
| Deferred long term liab | - | - | - | 0.24M | - |
| Other current liab | 0.14M | 0.78M | 0.23M | 0.47M | 0.12M |
| Common stock | - | 0.25M | 0.24M | 0.23M | 0.23M |
| Capital stock | 0.26M | 0.25M | 0.24M | 0.23M | 0.23M |
| Retained earnings | -81.37M | -78.70M | -76.70M | -74.08M | -72.39M |
| Other assets | - | - | 0.00M | 0.24M | - |
| Cash | 0.07M | 0.17M | 0.10M | 0.01M | 0.02M |
| Total current liabilities | 3.94M | 1.64M | 1.95M | 2.42M | 1.17M |
| Current deferred revenue | - | - | -0.03M | - | - |
| Net debt | 1.96M | 0.94M | 0.66M | 0.67M | 0.20M |
| Short term debt | - | 0.03M | 0.74M | 0.69M | 0.22M |
| Short long term debt | 1.78M | - | 0.71M | 0.69M | 0.22M |
| Short long term debt total | - | 1.11M | 0.76M | 0.69M | 0.22M |
| Other stockholder equity | - | 76.00M | 74.74M | 71.78M | 71.02M |
| Total current assets | 0.11M | 0.19M | 0.15M | 0.07M | 0.03M |
| Net tangible assets | - | - | - | -2.10M | -1.14M |
| Long term debt | 0.25M | 1.06M | - | - | - |
| Inventory | 0.00M | 0.00M | 0.03M | 0.03M | 0.00M |
| Accounts payable | 1.05M | 0.83M | 0.99M | 1.26M | 0.83M |
| Common stock total equity | - | - | - | 0.23M | 0.23M |
| Retained earnings total equity | - | - | - | -74.08M | -72.39M |
| Non currrent assets other | - | 0.00M | 0.02M | 0.24M | - |
| Non current assets total | 0.21M | 0.08M | 0.13M | 0.28M | 0.00M |
| Capital lease obligations | 0.02M | 0.05M | 0.08M | - | - |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | 0.00M | -0.00M | -0.04M | 0.00M |
| Change to liabilities | - | - | - | 0.94M | 1.22M |
| Total cashflows from investing activities | - | - | - | -0.04M | -0.04M |
| Net borrowings | 1.02M | 0.35M | -0.02M | 0.52M | 0.32M |
| Total cash from financing activities | 1.08M | 1.27M | 2.29M | 0.65M | 0.80M |
| Change to operating activities | - | - | - | 0.56M | 0.64M |
| Net income | -2.67M | -2.00M | -2.62M | -1.69M | -30.55M |
| Change in cash | -0.10M | 0.07M | 0.08M | -0.01M | -0.02M |
| Begin period cash flow | 0.17M | 0.10M | 0.01M | 0.02M | 0.05M |
| End period cash flow | 0.07M | 0.17M | 0.10M | 0.01M | 0.02M |
| Total cash from operating activities | -1.19M | -1.19M | -2.20M | -0.62M | -0.83M |
| Issuance of capital stock | 0.07M | 0.93M | 1.81M | 0.18M | 0.48M |
| Depreciation | 0.00M | 0.00M | 0.00M | 0.00M | 0.61M |
| Other cashflows from investing activities | - | - | -0.00M | - | - |
| Change to inventory | 0.00M | 0.03M | 0.00M | -0.03M | 0.00M |
| Sale purchase of stock | - | - | 0.00M | -0.05M | 0.48M |
| Other cashflows from financing activities | - | -0.01M | 2.30M | 0.84M | 0.32M |
| Change to netincome | - | - | - | 0.48M | 27.68M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.04M | 0.00M |
| Cash flows other operating | - | - | - | -0.33M | -0.01M |
| Cash and cash equivalents changes | - | - | - | -0.01M | -0.02M |
| Change in working capital | 0.39M | 0.51M | -0.03M | 1.16M | 1.33M |
| Stock based compensation | 1.12M | 0.38M | 0.46M | 0.48M | - |
| Other non cash items | 0.00M | -0.08M | -0.04M | -0.58M | 28.39M |
| Free cash flow | -1.19M | -1.19M | -2.20M | -0.66M | -0.83M |
Sector: Healthcare Industry: Medical Instruments & Supplies
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| UEEC United Health Products Inc |
-0.01 23.91% |
0.04 | - | - | 1445.03 | 5427.57 | 1726.93 | -10.10 |
| ISRG Intuitive Surgical Inc |
-3.79 0.88% |
426.74 | 43.30 | 31.35 | 12.25 | 7.35 | 11.63 | 30.22 |
| ESLOF EssilorLuxottica Société anonyme |
2.30 1.17% |
199.30 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
1.21 1.23% |
99.42 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
0.74 0.34% |
216.16 | 31.62 | 13.76 | 2.25 | 2.04 | 2.93 | 13.40 |
United Health Products, Inc. develops, manufactures, and markets hemostatic gauze products for the healthcare and wound care sectors in the United States. The company offers CelluSTAT hemostatic gauze products to absorb exudate/drainage from superficial wounds, as well as helps in controlling bleeding. It serves hospitals and surgery centers, clinics and physicians, military medical care providers, hemodialysis centers, nursing homes and assisted living, and veterinary hospitals; and EMS, fire departments, and other first responders, as well as dental, oral, and maxillofacial surgery offices. The company was formerly known as United EcoEnergy Corp. and changed its name to United Health Products, Inc. in September 2010. The company was incorporated in 1997 and is headquartered in Mount Laurel, New Jersey.
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian D. Thom | CEO & Chairman Pro Tempore | NA |
| Mr. Kristofer Heaton | VP of Fin. & Principal Financial Officer | 1979 |
| Mr. John Phillips | VP of Marketing & Commercial Strategy | NA |
| Dr. Gerard Abate M.D. | Chief Medical Director & Member of Medical Advisory Board | NA |
| Mr. Brian D. Thom | CEO, Interim Principal Financial Officer & Chairman | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.